Practically Speaking: Osi + Chemo in 1st Line EGFR mutated NSCLC

To be added to the distribution list, please email: DDeCastro@southlake.ca

In this episode of MedOncNow, Dr. Barb Melosky discusses 1st line Platinum + Pemetrexed in combination with Osimertinib for the 1st line treatment of EGFR mutated NSCLC. This is timely given we now have access to compassionate Osimertinib when given in combination with funded Platinum based doublet. 

Key Opinion Leader: 

Barb Melosky MD. FRCPC
Professor of Medicine, UBC
Medical Oncologist, BC Cancer
Vancouver, BC

Host:
Shaqil Kassam MD. MSc. FRCPC
skassam@southlake.ca
Medical Oncologist
Stronach Regional Cancer Centre, Newmarket, Ontario 

Previous episodes: https://www.blogtalkradio.com/medoncnow

X- @medoncnow